Source: Global Wellness Summit
  • Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit
  • The summit, taking place in Boston from November 30 to December 3, 2021, includes doctors, activists, and health care executives
  • Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford will host an in-person keynote conversation with Rick Doblin, PhD on December 1 at 4:10 pm EST
  • Psyence is a public life science biotechnology company focused on natural psychedelics
  • Psyence Group Inc. (PSYG) is unchanged on the day, trading at C$0.19 per share at 11:15 am EST

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.

The summit, taking place in Boston from November 30 to December 3, 2021, includes doctors, activists, and health care executives from a variety of research organizations including Harvard, MIT and Cleveland Clinic.

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford will host an in-person keynote conversation with Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of psychedelics and healing. The conversation with Doblin is scheduled for December 1st at 4:10 pm EST.

A psychedelic researcher and activist, Rick Doblin is widely recognized for his work de-stigmatizing psychedelics through evidence-based scientific research. His organization, MAPS, is sponsoring Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Mary-Elizabeth Gifford, chair of the non-profit Global Wellness Institute’s Psychedelics & Healing Initiative, leads Corporate Social Responsibility for the Psyence Group, where she works to democratize responsible psychedelic and nature-based solutions for mental health and wellness that also help heal and strengthen the wider community.  

Psyence is a public life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psyence Group Inc. (PSYG) is unchanged on the day, trading at C$0.19 per share at 11:15 am EST.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.